Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04614584
Other study ID # 20-30109
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 12, 2021
Est. completion date December 31, 2025

Study information

Verified date November 2023
Source San Francisco Department of Public Health
Contact Phillip Coffin, MD, MIA
Phone 628-217-6282
Email phillip.coffin@sfdph.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a drug-drug interaction (DDI) study of mirtazapine for methamphetamine (MA) use disorder (MUD) to ensure the safety of this medication in the presence of a relevant dose of MA for people actively-using MA. Aim 1: To determine if mirtazapine alters the cardiovascular response to IV MA. Aim 2: To determine if the pharmacokinetics of IV MA are altered by mirtazapine administration. Aim 3: To evaluate the above aims in the setting of concomitant administration of methadone. This study involves two simultaneous within-subject drug-drug interaction studies, each comprised of 12 participants. A total of 24 subjects will be enrolled who have methamphetamine use disorder who will be classified into 2 groups: (Group 1: no opioids; Group 2: opioid use disorder on methadone maintenance). Subjects will be randomized to the order of mirtazapine and placebo (i.e. one-half will receive mirtazapine first, then placebo; one-half will receive placebo first, then mirtazapine).


Description:

This is a drug-drug interaction (DDI) study of mirtazapine for methamphetamine (MA) use disorder (MUD) to ensure the safety of this medication in the presence of a relevant dose of MA for people actively-using MA. MA is a widely used psychostimulant associated with substantial morbidity and mortality. MA is more prevalent than many other drugs, including opioids, with 37 million users of MA and amphetamine worldwide and 1.4 million past-year users in the U.S. alone in 2016. The number of MA poisoning deaths has steadily risen in recent years, from >3,700 in 2014 to 10,333 in 2017. Importantly, MA has been recognized as contributing substantially to the U.S. opioid crisis, with about half of MA poisoning deaths also caused by opioids. In the U.S., the annual economic cost of MA use is estimated to be $23.4 billion and use is strongly associated with HIV transmission. There are no FDA-approved pharmacologic treatments for MUD, a major gap in addiction medicine, especially because behavioral interventions alone have limited efficacy and would likely benefit from adjunctive pharmacologic therapy. Investigators' prior clinical trials included a Phase IIa trial (N=60) and a replication Phase IIb trial (N=120) demonstrating that mirtazapine (an adrenergic, serotoninergic, and dopaminergic generic medication currently approved to treat depression) 30mg orally once daily reduced MA use among MA-dependent men who have sex with men (MSM) and transgender women. Investigators were directed to conduct a DDI study to ensure the safety of mirtazapine with MA. This research is particularly relevant given the overlap of MA use disorder and opioid use disorder (OUD), which could raise additional safety concerns. The primary objectives of this study are as follows: 1. To determine if mirtazapine 30mg daily alters the cardiovascular response to IV MA. The interaction of active medication (compared with placebo) with relevant doses of MA (30 mg) on cardiovascular (heart rate, blood pressure, QTc interval) parameters and adverse events, including serotonergic signs, will be assessed to gather safety information in the Phase I human laboratory. 2. To determine if mirtazapine alters the pharmacokinetics of IV MA. Pharmacokinetic parameters for MA and its major metabolites will be assessed over 48 hours under steady state mirtazapine (30 mg) or placebo, and relevant IV MA challenge (30 mg). 3. To evaluate the above aims in the setting of concomitant steady-state administration of morphine or methadone. Design This study involves two simultaneous within-subject drug-drug interaction studies, each comprised of 12 participants. A total of 24 subjects will be enrolled who have MA use disorder who will be classified into 2 groups: (Group 1: no opioids; Group 2: opioid use disorder on methadone maintenance). Subjects will be randomized to the order of mirtazapine and placebo (i.e. one-half will receive mirtazapine first, then placebo; one-half will receive placebo first, then mirtazapine). Procedures Screening assessments will be completed across two-to-four visits over 2 weeks. All screening assessments should be completed within 14 days after labs are drawn. All subjects will complete the following study visits: screening 1 and 2, enrollment/admission to inpatient stay, 14-day inpatient stay, 14-day post-discharge follow-up visit. After consent is obtained, eligibility will be determined over the following screening visits, including medical history and physical examination (including weight and height), review of systems, vital signs, concomitant medications, EKG, breathalyzer, labwork, SCID. Additional assessments will include the CDS-12, PSQI, TLFB for substance use, delayed discounting, BIS-11, Stroop Test, CUDIT-r, COWS, ACSA, BDI-II. On the day of enrollment, study staff will confirm eligibility and transport patient to hospital for admission. Participant will receive a test infusion of MA 30mg IV. If participant tolerates test infusion within defined parameters, participant will be formally enrolled and randomized. First dose of study drug will be administered the evening of admission. On the fifth hospital day, participant will undergo MA challenge (single-blind placebo and 30mg IV for subjective, cardiovascular, and PK assessments). PK draws will continue for 48 hours after infusion. Participant will begin the opposite condition on day 8 and complete the MA infusion procedures on day 12. After completion of PK studies on day 14, participant will be discharged. A post-discharge safety check will be completed 10 days after discharge (+/- 7 days).


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. English-speaking; 2. age 18-55 years inclusive; 3. meet DSM-V criteria for MA use disorder, as diagnosed via SCID; 4. provide MA-positive urine during screening; 5. have a resting heart rate of 50-90 6. have a systolic blood pressure = of 100-150 mm Hg, and diastolic blood pressure of 45-90 Hg within two days prior to admission; 7. have a baseline EKG that demonstrates normal sinus rhythm, QTc < 440 msec in men or QTc < 450 msec in women; 8. have acceptable safety lab data, ALT / AST<3x upper limit nL; est GFR >50; 9. if female (except females of non-childbearing potential-e.g., at least 1 year post-menopausal or surgically sterile), not pregnant confirmed by negative pregnancy test nor lactating and willing to use a medically approved method of birth control to prevent pregnancy during the trial and for 7 days after the last dose of study medication. 10) For those who also use opioids and are on methadone maintenance treatment (Group 2), urine positive for methadone and negative for buprenorphine on admission. Exclusion Criteria: 1. Have current cocaine, cannabis, or alcohol use disorder by DSM-V SCID; 2. current or past history of seizure disorder; 3. current ongoing treatment with psychotropic medications (e.g. antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics); 4. urine positive for MA and other unplanned drugs on the day of admission and breathalyzer results negative for alcohol; 5. any prior adverse reaction to MA; including chest pain or epileptic seizure; 6. major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar illness but excepting stable major depressive disorder, generalized anxiety disorder, etc.) as assessed by the SCID; 7. have a current neurological disorder (e.g., organic brain disease, dementia) or medical condition which would make study compliance difficult or compromise informed consent; 8. history of suicide attempt(s) in the past 90 days or current suicidal intent or plan by SCID; 9. evidence of untreated or unstable serious medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease including active tuberculosis infection; 10. seeking treatment for MA problems at the time of the study; 11. any serious medical or psychiatric AE after test infusion of MA 30mg IV (e.g. sustained SBP>200 or DBP>100; sustained pulse >(220-0.85xAge). 12. any other circumstances that, in the opinion of the investigators, would compromise participant safety and/or successful completion of the trial.

Study Design


Intervention

Drug:
Mirtazapine
Mirtazapine 30 mg PO daily x 4 days
Methamphetamine
Methamphetamine 30 mg IV once

Locations

Country Name City State
United States UCLA Medical Center Los Angeles California
United States San Francisco Department of Public Health San Francisco California
United States Substance Use Research Unit San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
San Francisco Department of Public Health University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Measures QT interval associated with combined use of methamphetamine and mirtazapine with and without concomitant methadone use 24 Days
Primary Metabolism of methamphetamine in presence of steady state mirtazapine Metabolism of methamphetamine in combination with mirtazapine Pharmacokinetics of methamphetamine in combination with mirtazapine with or without concomitant methadone use 14 Days
Secondary Impact of mirtazapine on subjective effects of methamphetamine reinforcement Subjective effects questionnaire 14 Days
Secondary Impact of mirtazapine on mood produced by methamphetamine use Addiction Research Inventory short form 14 days
Secondary Urge for stimulant use in the presence of mirtazapine Methamphetamine-based Questionnaire for Stimulant Urges 14 days
Secondary Preference for methamphetamine in the presence of mirtazapine Drug Purchase Task 14 days
Secondary Impact of mirtazapine on discounting in the presence of methamphetamine Delayed Discounting assessment 14 days
See also
  Status Clinical Trial Phase
Completed NCT04645940 - Fruquintinib Food Effect and Proton Pump Inhibitor Study Phase 1
Completed NCT04540965 - Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects Phase 1
Completed NCT04531072 - Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine Phase 4
Completed NCT03385525 - Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 Phase 1
Completed NCT05680792 - Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers N/A
Completed NCT05137548 - A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects Phase 1
Not yet recruiting NCT05525351 - The Application and Validation of Triple Drug Response Surface Models on Density Spectral Array in Clinical Anesthesia
Terminated NCT01980342 - Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz Phase 4
Completed NCT04080596 - DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin Phase 1
Recruiting NCT04593680 - Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men N/A
Active, not recruiting NCT04590417 - Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women N/A
Completed NCT05633147 - Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Phase 1
Completed NCT02391688 - Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail Phase 1
Completed NCT00806299 - Loperamide Grapefruit Juice Interaction PK Trial Phase 1
Completed NCT03336346 - Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
Completed NCT04818086 - Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Phase 1/Phase 2
Completed NCT03187015 - A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects Phase 1
Not yet recruiting NCT04463576 - Drug Interactions in Hospital Information System. The PRoSIT System..
Not yet recruiting NCT03920566 - The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1